Related Experiment Videos
Lymphomatoid granulomatosis. A case for aggressive therapy
1Brooke Army Medical Center, Fort Sam Houston, Texas 78234-6200.
Cancer
|September 15, 1989
Summary
Lymphomatoid granulomatosis, a rare vasculitis and lymphoma disorder, typically has a poor prognosis. Combination chemotherapy (MACOP-B) achieved a 3-year disease-free remission in a life-threatening case, suggesting an aggressive approach may be beneficial.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Lymphomatoid granulomatosis is a rare condition with overlapping features of vasculitis and lymphoma.
- Conventional treatments using steroids and single cytotoxic agents offer limited efficacy, resulting in a poor prognosis.
Observation:
- A patient presented with life-threatening lymphomatoid granulomatosis.
Findings:
- Successful treatment was achieved using a combination chemotherapy regimen: methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B).
- The patient attained complete remission and remained disease-free for over three years post-diagnosis.
Implications:
- This case supports an aggressive therapeutic strategy for severe lymphomatoid granulomatosis.
- Combination chemotherapy, such as MACOP-B, may represent a viable treatment option for refractory or severe cases.
- Further investigation into aggressive chemotherapy protocols for lymphomatoid granulomatosis is warranted.